Metabolic syndrome and diabetic atherothrombosis: Implications in vascular complications

被引:47
作者
Meerarani, P. [1 ]
Badimon, J. J. [1 ]
Zias, E. [1 ]
Fuster, V. [1 ]
Moreno, P. R. [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
metabolic syndrome; obesity; type 2 diabetes mellitus; atherosclerosis; peroxisome proliferator activator receptor; endothelial dysfunction; reactive oxygen species;
D O I
10.2174/156652406778018680
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Metabolic syndrome is characterized by the clustering of a number of metabolic abnormalities in the presence of underlying insulin resistance with a strong association with diabetes and cardiovascular disease morbidity and mortality. The disorder is defined in different ways, but the pathophysiology is attributable to insulin resistance. An increased release of free fatty acids (FFAs) from adipocytes block insulin signal transduction pathway, induce endothelial dysfunction due to increased reactive oxygen species (ROS) generation and oxidative stress. Dyslipidemia, associated with high levels of triglycerides and low concentrations of high density lipoproteins (HDLs), contributes to a proinflammatory state. Inflammation, the key pathogenic component of atherosclerosis, promotes thrombosis, a process that underlies acute coronary event and stroke. Tissue factor, a potent trigger of the coagulation cascade, is increased in diabetes with poor glycemic control. Therapeutic lifestyle changes (weight loss and physical activity) along with pharmacological interventions are recommended to prevent the complications of metabolic syndrome. In addition to statins, metformin, blood pressure lowering medications, interventions to increase HDLs are other important approaches to decrease the risk of cardiovascular disease. Furthermore, the peroxisome proliferator activated receptor (PPAR) alpha and gamma agonists are potent anti-inflammatory and anti-atherogenic agents that could both improve insulin sensitivity and the long-term cardiovascular risk. In this review we focus on the molecular and pathophysiological basis of metabolic syndrome, which augments diabetes (insulin resistance) and the contribution of neovascularization in the plaque progression in diabetes, leading to rupture and coronary thrombosis.
引用
收藏
页码:501 / 514
页数:14
相关论文
共 143 条
[71]  
Manrique Camila, 2005, J Clin Hypertens (Greenwich), V7, P471, DOI 10.1111/j.1524-6175.2005.04617.x
[72]   Improved endothelial function with metformin in type 2 diabetes mellitus [J].
Mather, KJ ;
Verma, S ;
Anderson, TJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) :1344-1350
[73]   Zinc modulates PPARγ signaling and activation of porcine endothelial cells [J].
Meerarani, P ;
Reiterer, G ;
Toborek, M ;
Hennig, B .
JOURNAL OF NUTRITION, 2003, 133 (10) :3058-3064
[74]   Carotid rupture and intraplaque hemorrhage: Immunophenotype and role of cells involved [J].
Milei, J ;
Parodi, JC ;
Alonso, GF ;
Barone, A ;
Grana, D ;
Matturri, L .
AMERICAN HEART JOURNAL, 1998, 136 (06) :1096-1105
[75]   Metabolic syndrome: Evaluation of pathological and therapeutic outcomes [J].
Miranda, PJ ;
DeFronzo, RA ;
Califf, RM ;
Guyton, JR .
AMERICAN HEART JOURNAL, 2005, 149 (01) :20-32
[76]   Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 [J].
Mokdad, AH ;
Ford, ES ;
Bowman, BA ;
Dietz, WH ;
Vinicor, F ;
Bales, VS ;
Marks, JS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (01) :76-79
[77]   Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation [J].
Moore, RE ;
Navab, M ;
Millar, JS ;
Zimetti, F ;
Hama, S ;
Rothblat, GH ;
Rader, DJ .
CIRCULATION RESEARCH, 2005, 97 (08) :763-771
[78]  
Moreno PR, 2000, CIRCULATION, V102, P2180
[79]   Intimomedial interface damage is increased beneath disrupted and adventitial inflammation atherosclerosis in the aorta - Implications for plaque vulnerability [J].
Moreno, PR ;
Purushothaman, KR ;
Fuster, V ;
O'Connor, WN .
CIRCULATION, 2002, 105 (21) :2504-2511
[80]   Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice [J].
Moulton, KS ;
Heller, E ;
Konerding, MA ;
Flynn, E ;
Palinski, W ;
Folkman, J .
CIRCULATION, 1999, 99 (13) :1726-1732